Abstract
A new Center for Radiopharmaceutical Cancer Research was established at the Helmholtz-Zentrum Dresden-Rossendorf in order to centralize radionuclide production, radiopharmaceutical production and the chemical and biochemical research facilities. The newly installed cyclotron is equipped with two beamlines, two target selectors and several liquid, gas and solid target systems. The cyclotron including the target systems and first results of beam characterization measurements as well as results of the radionuclide production are presented. The produced radionuclides are automatically distributed from the targets to the destination hot cells. This process is supervised and controlled by an in-house developed system.
Highlights
Introduction of the New Center forRadiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-RossendorfMartin Kreller 1, *, Hans Jürgen Pietzsch 1, Martin Walther 1, Henrik Tietze 2, Peter Kaever 2, Torsten Knieß 1, Frank Füchtner 1, Jörg Steinbach 1 and Stephan Preusche 1 *Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, BautznerHelmholtz-Zentrum Dresden-Rossendorf, Department of Research Technology, Bautzner Landstraße 400, Received: 20 December 2018; Accepted: 24 January 2019; Published: 30 January 2019 AbstractA new Center for Radiopharmaceutical Cancer Research was established at the Helmholtz-Zentrum Dresden-Rossendorf in order to centralize radionuclide production, radiopharmaceutical production and the chemical and biochemical research facilities
Radionuclide production, pharmacological research and the pharmaceutical production were located at different places at Helmholtz-Zentrum Dresden-Rossendorf (HZDR) [1]
18 MeV (14 MeV) and 30 MeV were executed to determine the profile of the proton beam hitting the solid target
Summary
The new Center for Radiopharmaceutical Cancer Research (ZRT), as it is shown, was established to centralize the main units: a high current proton cyclotron, a radiopharmaceutical production—GMP (Good manufacturing practice) unit including the quality control, laboratories for PET-radiochemistry, chemical laboratories, laboratories for biochemical investigations inside and outside the controlled area, laboratories for small animal imaging (small animal PET/CT, PET/MR, SPECT, OI, MR) and a laboratory animal facility (mice and rats). It is noteworthy that this entire quality control process has to be performed for every new batch the radiopharmaceutical is assessed. It is noteworthy that this entire quality control process has to be and should be completed within the shortest time possible, ordinarily within 30 min, to ensure adequate performed for every new batch and should be completed within the shortest time possible, ordinarily time for patient application. Within 30 min, to ensure adequate time for patient application
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
